Stability of Cervical Specimens in SurePath Medium for Human Papillomavirus Testing with the Roche Cobas 4800 Assay

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2013 Aug 2

PMID 23903540

Citations 8

Authors

Laura Gilbert

Elizabeth Oates

Samuel Ratnam

Affiliations

Soon will be listed here.

Abstract

The stability of cervical specimens in SurePath preservative fluid for human papillomavirus (HPV) testing with Roche cobas 4800 was determined using a panel of 308 pooled specimens from a colposcopy referral population. The SurePath specimens appeared to be stable for up to 10 weeks at ambient temperature for HPV testing with cobas 4800.

Citing Articles

An integrated isothermal nucleic acid amplification test to detect HPV16 and HPV18 DNA in resource-limited settings.

Kundrod K, Barra M, Wilkinson A, Smith C, Natoli M, Chang M Sci Transl Med. 2023; 15(701):eabn4768.

PMID: 37343083 PMC: 10566637. DOI: 10.1126/scitranslmed.abn4768.

HPV genotyping and p16/Ki-67 test significantly improve detection rate of high-grade cervical squamous intraepithelial lesion.

Lewitowicz P, Nasierowska-Guttmejer A, Rokita W, Adamczyk-Gruszka O, Gluszek S, Chrapek M Arch Med Sci. 2020; 16(1):87-93.

PMID: 32051710 PMC: 6963143. DOI: 10.5114/aoms.2018.80697.

Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens.

Chernesky M, Jang D, Escott N, Gilchrist J, Li J, Elit L Papillomavirus Res. 2017; 3:155-159.

PMID: 28720450 PMC: 5883188. DOI: 10.1016/j.pvr.2017.04.005.

Stability Study of Cervical Specimens Collected by Swab and Stored Dry Followed by Human Papillomavirus DNA Detection Using the cobas 4800 Test.

Lin C, Zeng X, Cui J, Liao G, Wu Z, Gao Q J Clin Microbiol. 2016; 55(2):568-573.

PMID: 27927922 PMC: 5277527. DOI: 10.1128/JCM.02025-16.

Molecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients with Nondiagnostic or Indeterminate Thyroid Nodules.

Kwon H, Kim W, Eszlinger M, Paschke R, Song D, Kim M Endocrinol Metab (Seoul). 2016; 31(4):586-591.

PMID: 27834083 PMC: 5195836. DOI: 10.3803/EnM.2016.31.4.586.

References

Mateos Lindemann M, Sanchez Calvo J, de Antonio J, Sanz I, Diaz E, Rubio M . Prevalence and Distribution of High-Risk Genotypes of HPV in Women with Severe Cervical Lesions in Madrid, Spain: Importance of Detecting Genotype 16 and Other High-Risk Genotypes. Adv Prev Med. 2011; 2011:269468. PMC: 3169348. DOI: 10.4061/2011/269468. View

Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, Freudenberg N . Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology. J Clin Microbiol. 2010; 49(3):1071-6. PMC: 3067681. DOI: 10.1128/JCM.01674-10. View

Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P . Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol. 2010; 49(2):557-64. PMC: 3043526. DOI: 10.1128/JCM.02147-10. View

Wong A, Fuller J, Pabbaraju K, Wong S, Zahariadis G . Comparison of the hybrid capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreservCyt medium. J Clin Microbiol. 2011; 50(1):25-9. PMC: 3256689. DOI: 10.1128/JCM.05400-11. View

Gage J, Sadorra M, Lamere B, Kail R, Aldrich C, Kinney W . Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests. J Clin Microbiol. 2011; 50(1):61-5. PMC: 3256696. DOI: 10.1128/JCM.05989-11. View

Castle P, Stoler M, Wright Jr T, Sharma A, Wright T, Behrens C . Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011; 12(9):880-90. DOI: 10.1016/S1470-2045(11)70188-7. View

Ki E, Kim H, Choi Y, Park J, Kang C, Lee A . Comparison of the Cobas 4800 HPV test and the Seeplex HPV4A ACE with the hybrid capture 2 test. Int J Med Sci. 2013; 10(2):119-23. PMC: 3547208. DOI: 10.7150/ijms.5460. View

Heideman D, Hesselink A, Berkhof J, van Kemenade F, Melchers W, Daalmeijer N . Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol. 2011; 49(11):3983-5. PMC: 3209101. DOI: 10.1128/JCM.05552-11. View

Naryshkin S, Austin R . Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening. Drug Healthc Patient Saf. 2012; 4:167-72. PMC: 3496968. DOI: 10.2147/DHPS.S37273. View

10.

Cox J, Castle P, Behrens C, Sharma A, Wright Jr T, Cuzick J . Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2012; 208(3):184.e1-184.e11. DOI: 10.1016/j.ajog.2012.11.020. View

11.

Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P . Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol. 2010; 48(8):2779-85. PMC: 2916571. DOI: 10.1128/JCM.00382-10. View

12.

Wright Jr T, Stoler M, Sharma A, Zhang G, Behrens C, Wright T . Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011; 136(4):578-86. DOI: 10.1309/AJCPTUS5EXAS6DKZ. View

13.

Stoler M, Wright Jr T, Sharma A, Apple R, Gutekunst K, Wright T . High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011; 135(3):468-75. DOI: 10.1309/AJCPZ5JY6FCVNMOT. View

14.

Moelans C, Oostenrijk D, Moons M, van Diest P . Formaldehyde substitute fixatives: effects on nucleic acid preservation. J Clin Pathol. 2011; 64(11):960-7. DOI: 10.1136/jclinpath-2011-200152. View